Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol

Brain Research

Volumn 1011, Issue 1, 2004, Pages 84-93

  Yanahashi, Satoshi ^a   Hashimoto, Kenji ^a   Hattori, Kotaro ^a,b,c   Yuasa, Shigeki ^a,d   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

CP 101,606; excitatory amino acid receptors: physiology, pharmacology and modulation; Extrapyramidal side effect; Fos; Haloperidol; Neurotransmitters, modulators, transporters, and receptors; NMDA receptor; NR2B subunit; Nucleus accumbens

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BD 1407; DIZOCILPINE; HALOPERIDOL; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE ANTAGONIST; PRAZOSIN; PROTEIN FOS; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; SIGMA OPIATE RECEPTOR; TRAXOPRODIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FOREBRAIN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; CATALEPSY; CELL COUNT; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; ETHYLENEDIAMINES; EXCITATORY AMINO ACID ANTAGONISTS; GENE EXPRESSION REGULATION; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED STRAINS; PIPERIDINES; PRAZOSIN; PROSENCEPHALON; PROTO-ONCOGENE PROTEINS C-FOS; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 2342636333     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.12.059     Document Type: Article

References (64)

1. Albin R.L., Makowiee R.L., Hollingsworth Z.R., Dure L.S.T., Penney J.B., Young A.B. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience. 46:1992;35-48
2. Amalric M., Ouagazzal A., Baunez C., Nieoullon A. Functional interactions between glutamate and dopamine in the rat striatum. Neurochem. Int. 25:1994;123-131
3. Baldessarini R.J., Frankenburg F.R. Clozapine: a novel antipsychotic drug. New Engl. J. Med. 324:1991;746-754
4. Baunez C., Nieoullon A., Amalric M. N-methyl-D-aspartate receptor blockade impairs behavioral performance of rats in a reaction time task: new evidence for glutamatergic-dopaminergic interactions in the striatum. Neuroscience. 61:1994;521-531
5. Boegman R.J., Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse. 22:1996;70-77
6. Bullock M.R., Merchant R.E., Carmack C.A., Doppenberg E., Shah A.K., Wilner K.D., Ko G., Williams S.A. An open-label study of CP-101, 606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. N. Y. Acad. Sci. 890:1999;51-58
7. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276
8. Casey D.E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology. 99:1989;S47-S53
9. Chazot P.L., Lawrence S., Thompson C.L. Studies on the subtype selectivity of CP-101, 606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology. 42:2002;319-324
10. Chenard B.L., Shalaby I.A., Koe B.K., Ronau R.T., Butler T.W., Prochniak M.A., Schmidt A.W., Fox C.B. Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J. Med. Chem. 34:1991;3085-3090
11. Claghorn J., Honigfield G., Abuzzahab F.S., Wanf R., Steinbook R., Tuason V., Klerman G. The risks and benefits of olanzapine versus chlorpromazine. J. Clin. Psychopharmacol. 7:1987;377-384
12. De Souza I.E., Meredith G.E. NMDA receptor blockade attenuates the haloperidol induction of Fos protein in the dorsal but not the ventral striatum. Synapse. 32:1999;243-253
13. Deutch A.Y., Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience. 46:1992;49-56
14. Deutch A.Y., Lee M.C., Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3:1992;332-341
15. DiChiari G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum: Ach/dopamine/NMDA interactions. Trends Neurosci. 17:1994;228-232
16. 2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience. 37:1990;287-294
17. Drouin C., Darracq L., Trovero F., Blanc G., Glowinski J., Cotecchia S., Tassin J.P. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J. Neurosci. 22:2002;2873-2884
18. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates. 1997;Academic Press, San Diego. Fig. 21
19. Fredriksson A., Archer T. Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice: II. Interactions with apomorphine. Neurotox. Res. 1:2000;249-259
20. Freud T.F., Powell J.F., Smith A.D. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendrite spines. Neuroscience. 13:1984;1189-1215
21. Gallagher M.J., Huang H., Lynch D.R. Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions. J. Neurochem. 70:1998;2120-2128
22. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. U. S. A. 87:1990;6912-6916
23. 3H]ifenprodil binding to sigma receptors in rat brain. Eur. J. Pharmacol. 236:1993;159-163
24. 3H]ifenprodil binding in rat brain. Eur. J. Pharmacol. 266:1994;67-77
25. Hattori K., Yagi T., Maekawa M., Sato T., Yuasa S. N-methyl-D-aspartate- induced c-fos expression in Fyn-deficient mice. Brain Res. 905:2001;188-198
26. Heimer L., Alheid G.F., De Olmos J.S., Groenewegen H.J., Haber S.N., Haqrlan R.E., Zahn D.S. The accumbens: beyond the core-shell dichotomy. J. Neuropsychiatry Clin. Neurosci. 9:1997;354-381
27. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47:1995;133-178
28. Hussain N., Flumerfelt B.A., Rajakumar N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience. 102:2001;391-399
29. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308
30. Kane J.M. Current problems with the pharmacotherapy of schizophrenia. Clin. Neuropharmacol. 18:1995;S156-S161
31. Kane J.M., Freeman H.L. Towards more effective antipsychotic treatment. Br. J. Psychiatry. 165:1994;22-33
32. Kutsuwada T., Kashiwabuchi N., Mori H., Sakimura K., Kushiya E., Araki K., Meguro H., Masaki H., Kumanishi T., Arakawa M., Mishina M. Molecular diversity of the NMDA receptor channel. Nature. 358:1992;36-41
33. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268:1994;335-345
34. Lindefors N., Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci. Lett. 115:1990;248-252
35. Liste I., Rozas G., Guerra M.J., Labandeira-Garcia J.L. Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors. Brain Res. 700:1995;1-12
36. Loftis J.M., Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 97:2003;55-85
37. Lynch D.R., Gallagher M.J. Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors. J. Pharmacol. Exp. Ther. 279:1996;154-161
38. MacGibbon G.A., Lawlor P.A., Hughes P., Young D., Dragunow M. Differential expression of inducible transcription factors in basal ganglia neurons. Mol. Brain Res. 34:1995;294-302
39. Maj J., Skuza G., Rogoz Z. Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J. Neural Transm., Parkinson's Dis. Dement. Sect. 6:1993;53-62
40. Matsumoto R.R., Bowen W.D., Tom M.A., Vo V.N., Truong D.D., De Costa B.R. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur. J. Pharmacol. 280:1995;301-310
41. McGeorge A.J., Faull R.L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537
42. Meguro H., Mori H., Araki K., Kushiya E., Kutsuwada T., Kumanishi T., Arakawa M., Sakimura K., Mishina M. Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNA. Nature. 357:1992;70-74
43. 2+ release. Trends Pharmacol. Sci. 16:1995;503-513
44. Nakajima T., Daval J.L., Morgan P.F., Post R.M., Marangos P.J. Adenosinergic modulation of caffeine-induced c-fos mRNA expression in mouse brain. Brain Res. 501:1989;307-314
45. Nash J.E., Brotchie J.M. Characterization of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov. Disord. 17:2002;455-466
46. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc. Natl. Acad. Sci. U. S. A. 89:1992;4270-4274
47. Okiyama K., Smith D.H., White W.F., Richter K., McIntosh T.K. Effects of the novel NMDA antagonists CP-98, 113, CP-101, 581 and CP-101, 606 on cognitive function and regional cerebral edema following experimental brain injury in the rat. J. Neurotrauma. 14:1997;211-222
48. Presley R.W., Menetray D., Levine J.D., Basbaum A.I. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord. J. Neurosci. 10:1990;323-335
49. Rawls S.M., Baron D.A., Geller E.B., Adler M.W. Sigma sites mediate DTG-evoked hypothermia in rats. Pharmacol. Biochem. Behav. 73:2002;779-786
50. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328
51. Robertson G.S., Vincent S.R., Fibiger H.C. D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience. 49:1992;285-296
52. Romieu P., Martin-Fardon R., Maurice T. Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference. NeuroReport. 11:2000;2885-2888
53. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci. 18:1995;57-58
54. Sheng M., Greenberg M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron. 4:1990;477-485
55. Smith A.D., Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci. 13:1990;259-265
56. Standaert D.G., Testa C.M., Young A.B., Penny J.B. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343:1994;1-16
57. Starr M.S. Glutamate/dopamineD1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293
58. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101, 606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp. Neurol. 163:2000;239-243
59. Torgny H.S. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Rev. 31:2000;320-329
60. Watanabe M., Inoue Y., Sakimura K., Mishina M. Distinct distributions of five N-methyl-D-aspartate receptor channel subunit mRNAs in the forebrain. J. Comp. Neurol. 338:1993;377-390
61. Whitton P.S., Maione S., Biggs C.S., Fowler L.J. N-methyl-D-aspartate receptors modulate extracellular dopamine concentration and metabolism in rat hippocampus and striatum in vivo. Brain Res. 635:1994;312-316
62. Young C.D., Bubster M., Meltzer H.Y., Deutch A.Y. Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation. Psychopharmacology. 144:1999;255-263
63. Zahm D.S. An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci. Biobehav. Rev. 24:2000;85-105
64. Ziolkowska B., Hollt V. The NMDA receptor antagonist MK-801 markedly reduces the induction of c-fos gene by haloperidol in the mouse striatum. Neurosci. Lett. 156:1993;39-42